Operating Assets, Liabilities, and Contingent Liabilities

(20) Property, plant, and equipment

Accounting and measurement policies

Recognition and initial measurement

The Group receives monetary and non-monetary government grants. It does not exercise the option of recognizing non-monetary grants, such as allocated emission certificates, at fair value. Monetary grants related to assets are deducted from the respective carrying amount.

Advance payments are disclosed together with the assets under construction.

Subsequent measurement

Subsequent measurement is at amortized cost.

Property, plant and equipment is depreciated using the straight-line method over the useful life of the asset concerned, and the corresponding expenses are allocated to the respective functional costs. Depreciation of property, plant and equipment is primarily based on the following useful lives:

Property, plant and equipment – Useful lives

 

 

Useful life

Production buildings

 

No more than 40 years

Administration buildings

 

No more than 40 years

Plant and machinery

 

6 to 25 years

Operating and office equipment, other facilities

 

3 to 10 years

The useful lives of the assets are reviewed regularly and adjusted if necessary.

An impairment test is performed if there are indications of impairment. External and internal information is used in this context. In the event of impairment, an impairment loss is recognized under other operating expenses. Impairment losses are reversed up to amortized cost and reported in other operating income if the original reasons for impairment no longer apply.

Significant discretionary decisions and sources of estimation uncertainty

Determination of depreciation

Assumptions and estimates are required in determining the appropriate useful life and the expected residual value in order to calculate the amount of depreciation on property, plant and equipment. This applies in particular to the determination of the underlying remaining useful life. In making these estimates, the Group considers the useful lives of the property, plant and equipment derived from past experience, among other things.

Identification of a need to recognize impairment loss and reverse impairment loss

Discretionary decisions are required in the identification of objective evidence of impairment as well as in identifying the need to reverse impairment of property, plant and equipment.

Property, plant and equipment

€ million

 

Land, land rights and buildings

 

Plant and machinery

 

Other facilities, operating and office equipment

 

Construction in progress

 

Total

Cost as of Jan. 1, 2023

 

5,976

 

6,228

 

1,879

 

2,429

 

16,513

Additions due to business combinations

 

 

 

 

 

Other Additions

 

169

 

32

 

56

 

1,723

 

1,981

Disposals due to divestments/Reclassification to assets held for sale

 

 

 

 

 

Other Disposals

 

-85

 

-93

 

-82

 

-18

 

-278

Transfers

 

385

 

542

 

120

 

-1,053

 

-6

Currency translation difference

 

-119

 

-84

 

-27

 

-37

 

-266

Dec. 31, 2023

 

6,326

 

6,625

 

1,946

 

3,045

 

17,943

 

 

 

 

 

 

 

 

 

 

 

Accumulated depreciation and impairment losses as of Jan. 1, 2023

 

-2,588

 

-4,319

 

-1,380

 

-21

 

-8,308

Depreciation

 

-332

 

-389

 

-173

 

 

-895

Impairment losses

 

-1

 

-8

 

-2

 

-12

 

-23

Reversals of impairment losses

 

 

1

 

 

 

1

Disposals due to divestments/Reclassification to assets held for sale

 

 

 

 

 

Disposals

 

67

 

88

 

77

 

 

233

Transfers

 

-9

 

1

 

5

 

3

 

1

Currency translation difference

 

43

 

43

 

19

 

1

 

106

Dec. 31, 2023

 

-2,820

 

-4,584

 

-1,454

 

-29

 

-8,887

 

 

 

 

 

 

 

 

 

 

 

Net carrying amounts as of Dec. 31, 2023

 

3,506

 

2,042

 

492

 

3,016

 

9,056

 

 

 

 

 

 

 

 

 

 

 

Cost as of Jan. 1, 2024

 

6,326

 

6,625

 

1,946

 

3,045

 

17,943

Changes in the scope of consolidation

 

3

 

3

 

2

 

2

 

10

Additions

 

325

 

36

 

52

 

1,677

 

2,091

Reclassification to assets held for sale

 

-185

 

-449

 

-61

 

-36

 

-731

Disposals

 

-126

 

-179

 

-122

 

-15

 

-442

Transfers

 

1,008

 

958

 

226

 

-2,211

 

-20

Currency translation difference

 

128

 

83

 

12

 

38

 

261

Dec. 31, 2024

 

7,480

 

7,077

 

2,054

 

2,500

 

19,112

 

 

 

 

 

 

 

 

 

 

 

Accumulated depreciation and impairment losses as of Jan. 1, 2024

 

-2,820

 

-4,584

 

-1,454

 

-29

 

-8,887

Depreciation

 

-365

 

-433

 

-184

 

 

-982

Impairment losses

 

-34

 

-21

 

-2

 

-28

 

-85

Reversals of impairment losses

 

 

 

 

 

Disposals due to divestments/Reclassification to assets held for sale

 

132

 

387

 

49

 

12

 

580

Disposals

 

95

 

169

 

119

 

6

 

389

Transfers

 

3

 

17

 

-16

 

-4

 

Currency translation difference

 

-47

 

-46

 

-10

 

 

-103

Dec. 31, 2024

 

-3,036

 

-4,510

 

-1,499

 

-42

 

-9,087

 

 

 

 

 

 

 

 

 

 

 

Net carrying amounts as of Dec. 31, 2024

 

4,445

 

2,567

 

556

 

2,457

 

10,025

The disposals due to divestments/Reclassification to assets held for sale related to the planned divestment of the Surface Solutions business. The additions from business combinations primarily related to the acquisition of Mirus Bio LLC, United States, and Unity SC, France (see Note (6) “Acquisitions and divestments”).

The individual additions to construction in progress in fiscal 2024 with an investment volume of more than € 50 million are presented below:

Property, plant and equipment – Additions

Business sector

 

Investment project

 

Country

Life Science

 

Membrane factory

 

Ireland

Life Science

 

Capacity for Drug Safety Testing Capacity (CTS)

 

USA

Healthcare

 

Research Center

 

Germany

Healthcare

 

Technology Center

 

Germany

Electronics

 

Capacity for Semiconductor Solutions

 

Taiwan

Monetary grants amounted to € 78 million in fiscal 2024 (2023: € 88 million) and related to a number of different items. They comprised grants related to assets as well as grants related to income. Some of the aforementioned grants are tied to the recruitment of an agreed number of employees at the respective sites. The Group expects to satisfy the conditions for receiving the grants.

The impairments of € 85 million in fiscal 2024 (2023: € 23 million) included a mid-double-digit million-euro amount for the impairment of property, plant and equipment in France in the Life Science and Healthcare business sectors.

Share this page: